Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.
Amita Patnaik
Research Funding - Merck
Soonmo Peter Kang
Employment or Leadership Position - Merck
Stock Ownership - Merck
Anthony W. Tolcher
Consultant or Advisory Role - AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Ambit BioSciences (U); Amgen (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Bayer (U); BIND Biosciences (U); Biogen Idec (U); Celgene (U); Curis (U); Daiichi Sankyo (U); Dendreon (U); Dicerna (U); EMD Serono (U); Endo Pharmaceuticals (U); Enzon (U); Exelixis (U); FivePrime (U); Galapagos (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); ImClone Systems (U); Insert Therapeutics (U); Intellikine (U); Invivis (U); Janssen Global Services, LLC (U); Johnson & Johnson (U); Merck (U); Micromet (U); Nektar (U); Neumedicines (U); Novartis (U); Onyx (U); Otsuka (U); Pfizer (U); PPD Development (U); ProNAi (U); Regeneron (U); Sanofi (U); Spectrum Pharmaceuticals (U); SuperGen (U); Symphogen (U); Triphase Accelerator Corp (U); Vaccinex (U); Veeda Oncology (U); Zyngenia (U)
Research Funding - Merck
Drew Warren Rasco
Consultant or Advisory Role - Celgene (U)
Research Funding - Merck
Kyriakos P. Papadopoulos
Research Funding - MK-3475 Merck
Muralidhar Beeram
No relevant relationships to disclose
Ronald Drengler
No relevant relationships to disclose
Cong Chen
Employment or Leadership Position - Merck
Stock Ownership - Merck
Lon Smith
No relevant relationships to disclose
Crystal Perez
No relevant relationships to disclose
Kevin Gergich
Employment or Leadership Position - Merck
Stock Ownership - Merck
Manfred Lehnert
Employment or Leadership Position - Merck
Stock Ownership - Merck